Fogari R, Zoppi A
Department of Internal Medicine and Therapeutics, Policlinico S. Matteo, University of Pavia, Italy.
J Cardiovasc Pharmacol. 1989;14 Suppl 9:S68-71.
Postinfarction treatment trials have demonstrated that beta-blockers are beneficial after myocardial infarction (MI), significantly reducing postinfarction cardiac mortality and nonfatal reinfarction, aside from bringing about an improved quality of life. Such cardioprotective action is probably mediated by both antiarrhythmic and anti-ischemic effects of these drugs. Beta-Blockers without ISA seem to be more effective in reducing cardiac mortality than those with ISA, which is probably due to their different effects on heart rate. Patients deriving major benefit from beta-blocker therapy after MI should be "high risk," elderly, and, perhaps, hypertensive patients. The suitable duration of postinfarction beta-blocker therapy is unknown: results from recent long-term trials speak in favor of continuous postinfarction beta-blocker therapy.
心肌梗死后治疗试验表明，β受体阻滞剂在心肌梗死（MI）后有益，除了能改善生活质量外，还能显著降低心肌梗死后的心脏死亡率和非致命性再梗死。这种心脏保护作用可能是由这些药物的抗心律失常和抗缺血作用介导的。无内在拟交感活性（ISA）的β受体阻滞剂在降低心脏死亡率方面似乎比有ISA的更有效，这可能是由于它们对心率的不同影响。心肌梗死后从β受体阻滞剂治疗中获得主要益处的患者应该是“高危”、老年且可能是高血压患者。心肌梗死后β受体阻滞剂治疗的合适持续时间尚不清楚：近期长期试验的结果支持心肌梗死后持续使用β受体阻滞剂治疗。
